Microbial CRDMO for Sterile Fill-Finish: Yaohai Review

For biopharmaceutical innovators evaluating a microbial CRDMO partner capable of delivering reliable sterile fill and finish services, Yaohai Bio-Pharma presents a case worth examining closely. Formally known as Yaohai Bio-Pharmaceutical, the company has built its identity around microbial expression systems rather than generic mammalian platforms, positioning itself as a specialized Contract Research, Development, and Manufacturing Organization (CRDMO) that covers everything from early R&D through GMP manufacturing, including drug product fill-finish.

Why Microbial Specialization Matters for Fill-Finish Quality

Many biopharma programs struggle with low yields and stability issues in mammalian expression systems, along with severe aggregation problems in scFv/Fab fragments. These upstream and midstream challenges ultimately affect the quality of the final drug product that reaches fill-finish operations. Yaohai addresses this through its E. coli expression platform and yeast expression platform, both engineered for high-yield microbial production. The company’s proprietary refolding technology specifically targets aggregation in scFv/Fab fragments, helping ensure that material entering downstream purification and formulation stages is structurally sound before it ever reaches the fill-finish line.

Drug Product Manufacturing and Fill-Finish Infrastructure

Yaohai’s manufacturing footprint includes 7,500L total drug substance capacity spread across 5 production lines, ranging from 50L small-scale to 2000L large-scale fermentation, paired with 2 drug product fill-finish lines. This combination allows the company to move a program from fermentation through purification into finished drug product without handing off to a separate manufacturing partner. According to the company’s own capability documentation, formulation development work includes formulation screening and optimization, lyophilization process development, and injectable formulation development, including prefilled syringe-related capabilities, along with stability studies and drug product process transfer. Support is also extended to selected liquid, ophthalmic, oral, and inhalation formulations, subject to product-specific assessment.

This end-to-end structure is reinforced by what Yaohai describes as a CRDMO one-stop service model, spanning molecular design and construct development, strain development, upstream and downstream process development, process scale-up, GMP drug substance manufacturing, and finally drug product manufacturing with sterile fill-finish services for applicable products.

Quality Infrastructure Behind Sterile Manufacturing

Sterile fill-finish operations depend heavily on the surrounding quality system. Yaohai operates Triple ISO-certified and EU QP-audited facilities, and its quality control function is built around 50+ analytical methods covering protein identity, purity, concentration, potency, and impurity analysis, along with physicochemical and microbiological testing, stability studies, specification development, and batch release testing. These elements are presented as part of an integrated system connecting CMC process development, GMP manufacturing, and global regulatory affairs rather than standalone functions.

The company reports a 98% technology transfer success rate and a 98% successful project delivery rate, metrics it attributes to the reliability of moving programs from process development into GMP-scale manufacturing, including fill-finish. A 95% client retention rate is also cited as an indicator of sustained client satisfaction across its service lines.

Track Record Across Development Stages

Yaohai states it has completed 200+ successful projects, currently supports 9 Phase III clinical projects and 15 Phase II clinical projects, and has supported over 100 IND/Phase I projects. Since 2022, the company has supported over 800 RNA projects for universities and biotechs. While these figures span the company’s full service portfolio rather than being exclusive to fill-finish, they reflect the breadth of GMP manufacturing experience — spanning clinical and, where applicable, commercial-scale production — that underpins the company’s drug product operations.

Global Regulatory Reach Supporting Market Access

A sterile fill-finish capability is only as useful as the regulatory pathway that follows it. Yaohai’s Global Regulatory Affairs service line includes CMC documentation and regulatory submission support, process validation and technology transfer, and ongoing quality management. The company cites a track record in US-China dual submissions and Australian filings, along with successful European and Australian regulatory registrations for clinical trials. These capabilities matter for companies whose finished drug products, once filled and sealed, must still clear regulatory review in the USA, China, Europe, and Australia — the four markets Yaohai lists as part of its global business coverage.

Supporting Platforms Beyond Fill-Finish

While fill-finish sits at the end of the manufacturing chain, Yaohai’s broader technical platforms feed into product quality at that stage. The RNASUP mRNA platform, combined with SORT LNP and AbLNP encapsulation technologies, supports mRNA production for therapeutic and vaccine applications. The company also offers Plasmid DNA production for viral vector construction and cell therapy applications, Nanobody (VHH) production noted for achieving ultra-high yield and superior stability, and support for circRNA development in gene therapy contexts. Each of these modalities, when advanced to drug product stage, draws on the same fill-finish and quality infrastructure described above.

Cost and Time Considerations

Yaohai states that, compared with other CDMO companies, clients see an average of 20% cost savings and 30% time savings. This is attributed to the one-stop service structure that connects R&D and process development directly to GMP manufacturing, reducing the handoffs that typically occur when drug substance and drug product work are split across separate vendors.

Customer Cases Reflecting Delivery Outcomes

Among the cases documented by the company, one describes a successful US-China dual submission for a biopharmaceutical asset, another describes successful European and Australian regulatory registrations for clinical trials, and a third describes clinical-grade nanobody (VHH) production achieving ultra-high yield and superior stability. A separate case notes that over 800 RNA projects have been supported for universities and biotechs since 2022. These examples illustrate how the company’s regulatory and manufacturing capabilities, including those supporting sterile fill-finish, have translated into documented program outcomes.

Summary Assessment

For organizations assessing a microbial CRDMO with sterile fill and finish capability, Yaohai Bio-Pharma’s profile combines microbial expression specialization, an integrated drug substance-to-drug product manufacturing footprint of 7,500L capacity across 5 production lines and 2 fill-finish lines, a quality system built on 50+ analytical methods and Triple ISO/EU QP-audited facilities, and a regulatory track record spanning the US, China, Europe, and Australia. Founded in 2010 and reporting more than 16 years of specialization in microbial expression systems, the company presents a one-stop service model intended to carry biologic, nucleic acid, and related modalities from early development through to finished, market-ready product.

https://www.yaohaibio-pharma.com/
Yaohai Bio-Pharma